Tessellate BIO, Omico & CMRI Collab to Accelerate Discovery of Synthetic Lethal Precision Therapies

Tessellate BIO, Omico & CMRI Collab to Accelerate Discovery of Synthetic Lethal Precision Therapies

By, Admin 3 October 2024

Tessellate BIO, Omico & CMRI collaborate to accelerate discovery of synthetic lethal precision therapies to address ‘ALT’ cancers

Overview

Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, announces a collaboration with CMRI, a leading Australian paediatric medical research institute, and Omico, an organization uniting over 50 world-class cancer institutes in Australia and New Zealand.

About the Collaboration

  • The collaboration has been established to advance the understanding of the prevalence of alternative lengthening of telomeres (ALT) across tumour types and the genetic factors involved, and thereby accelerate the development of precision medicine tools and new cancer therapies. 
  • ALT is a mechanism that some cancer cells use to maintain the integrity of their telomeres during cell division, and is essential for their unlimited replicative potential. 
  • It builds on the collaboration with Tessellate BIO co-founder Prof. Hilda Pickett at CMRI.

Sample Collection fro MoST Program

The large genomically-characterized patient sample cohort was collected by Omico as part of the MoST (Cancer Molecular Screening and Therapeutics) program and has already allowed the partners to explore ALT prevalence in primary tissue samples utilizing the C-Circle Assay, the expected gold standard for establishing ALT status.

While ALT has been detected in 10 to 15% of all cancers, it has primarily been studied in cancers with ALT prevalence exceeding 50%, e.g., soft tissue sarcomas and osteosarcomas. Initial results of the Tessellate BIO – Omico – CMRI collaboration are already revealing the presence of ALT in cancers that were previously not associated with this mechanism of telomere maintenance.

Novel Therapies

Tessellate BIO is developing novel therapies specifically targeting ALT cancers and the collaboration contributes to its leadership position in the field of ALT biology and drug discovery.

Words from the CSO: Tessellate BIO

  • Dr. Jurgen Moll, Tessellate BIO CSO, said: “The Omico – CMRI collaboration is instrumental for us to identify subpopulations of patients in different cancer indications that are driven by ALT and for which we are developing targeted drugs.” 
  • In addition, we are excited about the opportunity to validate the C-Circle Assay to detect ALT+ cancer patients by screening a wide range of human cancer samples. This brings us closer to our aim: to make the C-Circle Assay the future gold standard for identifying these patients in the clinic – true precision medicine.

Words from the CEO: CMRI

  • Prof. Roger Reddel, CEO of CMRI and chair of the Tessellate BIO scientific advisory board, said: “Synthetic lethality has huge potential for the development of new cancer therapies but has so far been directed to only a small proportion of cancer types by targeting of Homologous Recombination Deficiency (HRD).
  • This collaboration has been established to make a meaningful contribution to expanding lethality beyond HRD into ALT+ cancers through the development of new therapies and associated companion diagnostics.

Words from the CSO: Omico

Prof. David Thomas, Omico chief science and strategy officer, said: “We welcome this collaboration and to publishing the results in due course, with the aim to further the understanding of ALT cancers in the broader scientific community and eventually to develop new tools and therapies to improve patients’ lives.”

Words from the CEO: Tessellate BIO

“Tessellate BIO is delighted with the collaboration and anticipates that the results will help therapies for ALT cancers become available to the right patients with the highest probability to benefit from them. The collaboration partners plan to publish their findings in the future,” said Tessellate BIO CEO Andree Blaukat.

Tessellate BIO Work on Cancer

  • Tessellate BIO discovers and develops novel precision oncology medicines with the mission to turn cancer patients into cancer survivors. 
  • A private preclinical stage biotechnology company, Tessellate BIO is redefining Synthetic Lethality by developing drugs that target unexplored or difficult to drug pathways beyond HRD.

About Omico

Omico (Australian Genomic Cancer Medicine Centre) is a national, not-for-profit organisation enabling a network of research and treatment centers that facilitates, supports, and promotes clinical trials in genomic cancer medicine.

About CMRI

  • CMRI (Children’s Medical Research Institute), is a medical research institute located in Sydney, Australia. 
  • The ALT cancer mechanism was first discovered at CMRI in 1995, and the research into telomere biology and ALT cancers remains a key focus of the institute to this day.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!